The treatment with PEA significantly attenuates aberrant DNA methylation in Pcyt2 + /- liver and corrects the DNA methylation of genes involved in the pathogenesis of NASH, indicating its therapeutic potential. This evidence concerns the gene PCYT2 and metabolic dysfunction-associated steatohepatitis.